Health insurer Molina cuts annual profit targets again as medical costs weigh

Molina Healthcare (MOH.N) has again lowered its annual profit forecast to at least $19.00 per share, down from a prior range of $21.50-$22.50, citing persistently higher medical care costs, particularly within its marketplace health insurance plans. This revision, which follows a Q2 adjusted profit miss of $5.48 per share against analyst estimates of $5.79, sent its shares down 7% in extended trading. The move underscores a broader industry challenge, as peers like Elevance Health and UnitedHealth have also faced increased medical claims, impacting profitability for health insurers, especially those with government-backed Medicare and Medicaid plans.

Analysis

Molina Healthcare has issued its second downward revision to its annual profit forecast this month, now projecting at least $19.00 per share, a substantial reduction from the previous range of $21.50 to $22.50. This guidance cut, which triggered a 7% decline in its shares in extended trading, is attributed to persistently high medical care costs, with a disproportionate impact from its marketplace health insurance plans and revised cost assumptions for the second half of the year. The warning is substantiated by the company's second-quarter performance, where adjusted profit of $5.48 per share missed analyst estimates of $5.79. This is not an isolated issue but reflects a systemic trend across the health insurance sector; peers Elevance Health have also cut profit forecasts, while industry bellwether UnitedHealth has suspended its guidance entirely due to the same cost pressures that have been escalating over the past two years.

Key Decisions for Investors

• Given the magnitude of the guidance cut and the Q2 earnings miss, investors should reconsider their position in Molina, as the phrase 'at least $19.00' suggests further downside risk if medical cost trends do not stabilize in the second half.
• The concurrent negative actions from Molina, Elevance, and UnitedHealth signal a sector-wide margin compression, warranting a portfolio review of all health insurance holdings, particularly those with significant exposure to government-backed and marketplace plans.
• Investors should closely monitor forward-looking medical cost trend data and management commentary on cost containment strategies, as these will be the primary drivers for the sector's performance and any potential entry or exit points.